Pediatric Brain Cancer:
U.S. Phase 1 Clinical Trial

 

Not Yet Recruiting

Pediatric Brain
Cancer:  U.S. Phase
1 Clinical Trial

 

Not Yet Recruiting

Pediatric
Brain
Cancer:
U.S. Phase
1 Clinical
Trial

 

Not Yet Recruiting

Trial Information

Pediatric brain cancer is relatively rare. However, cancer is the leading cause of death by disease among children in the U.S.  Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.

Plus Therapeutics is developing the Rhenium (186Re) Obisbemeda radiotherapeutic for the treatment of rare, frequently fast-growing pediatric brain and spinal cord tumors with a poor prognosis – ependymoma and high-grade glioma (HGG).  The ReSPECT-PBC (Pediatric Brain Cancer) U.S. Phase 1 Clinical Trial is planned to start in 2025.

“Children with brain tumors have limited options & 186RNL delivered with a minimally invasive procedure could be an important new potential option for these patients.”

Michael G. DeCuypere, MD, PhD, FAANS

Northwestern University Feinberg School of Medicine

Principal Investigators

There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.

Ashley S. Plant, M.D.

Lurie Children’s Hospital of Chicago

SPECIALTIES:  CANCER & BLOOD DISORDERS

Ashley S. Plant, M.D. is an attending physician in neuro-oncology at Ann and Robert H. Lurie Children’s Hospital of Chicago and is an Assistant Professor of Pediatrics at Northwestern University. Dr. Plant received her medical degree from Stanford University School of Medicine. She completed her pediatrics residency at University of California, Los Angeles and her pediatric hematology/oncology fellowship at Dana Farber Cancer Institute/Boston Children’s Hospital. She completed additional training in neuro-oncology at Dana Farber Cancer Institute. Her research focus includes immunotherapy and the immune microenvironment as well as early phase clinical trial design for pediatric brain tumors.

Trial Locations

Please visit this website regularly for updates as new locations are added.

Lurie Children’s Hospital

Chicago, Illinois

What Can You Do Next?

Participating in a clinical trial is an important decision.  If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Request Information

12 + 6 =

News

 
April 9, 2024
 
 

November 29, 2023

Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe

  • Presentation titled “Re-186 Radiolabelled NanoLiposomes for Rare Brain and Spinal Cord Tumors”

June 8, 2023

Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

  • Plus Therapeutics announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.

August 21, 2021

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer

June 10, 2021

Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference

Updates

Head for the Cure Austin

Join some of the Plus Therapeutics team at the @HeadfortheCure 5K in Austin, TX on March 24! They will be out supporting the local community, cancer research, and "Defeating Brain Cancer Step by Step." We hope to see you there 🏃🏃‍♂️🏃‍♀️ Event information:...

read more

Corporate Presentation

AVAILABLE NOW: The new Plus Therapeutics corporate presentation, which reflects our current data, milestones, and pipeline, is on our website. View it directly here: https://bit.ly/3PiHClj Questions about anything or interested in learning more? Visit our website at...

read more

“Glioblastoma AKA GBM” Sponsorship

We are thrilled to announce our sponsorship with @glioblastomaresearch this upcoming season on their "Glioblastoma AKA GBM" podcast! 🧠 We appreciate their goal of raising awareness and funds for new global, cutting-edge research to find a cure for Glioblastoma and...

read more

Rare Disease Day 2024

Today on leap day, the rarest day of the year, we celebrate Rare Disease Day along with the NIH and other organizations. Plus Therapeutics is dedicated to developing innovative, targeted radiotherapeutics for adult & pediatric patients with rare &...

read more

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.